<DOC>
	<DOCNO>NCT00002011</DOCNO>
	<brief_summary>To determine safety patient tolerance UVAR Photopheresis System ( extracorporeal photopheresis ) Treatment AIDS-Related Complex ( ARC ) .</brief_summary>
	<brief_title>The Therakos UVAR Photopheresis System Treatment AIDS-Related Complex</brief_title>
	<detailed_description>Treatment involve patient ingest 8-methoxsalen ( 8-MOP ) mouth approximately two hour prior photopheresis session . The photopheresis instrument separate patient 's white blood cell plasma blood component return majority blood component patient . The separated white blood cell plasma expose UVA ( Ultraviolet A ) light outside body . The UVA light photoactivates 8-MOP drug locate DNA collect cell . After exposure , patient photoactivated white blood cell return patient venous access .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Diagnosis AIDSrelated complex ( ARC ) . Veins provide adequate access . Negative drug screen drug abuse zidovudine ( AZT ) . Be willing adhere protocol sign patient inform consent prior study entry . Live within adequate commute distance treatment center . Not investigational drug/device . Be 18 80 year old minimum age requirement may affect state regulation specific medical condition . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Inability tolerate extracorporeal volume loss leukocyteenrichment phase . Photosensitive disease , porphyria systemic lupus erythematosus . Care must take select patient require drug ( either systemically topically ) course study photosensitize potential phenothiazine , tetracycline , sulfonamide chlorothiazide . Renal insufficiency creatinine &gt; 3 mg/dl . Symptoms toxic effect ( World Health Organization Criteria ) result previous therapy . Severe emotional , behavioral psychiatric problem opinion investigator would result poor compliance treatment regimen . Idiosyncratic hypersensitivity reaction 8MOP compound . History active Pneumocystis carinii pneumonia , opportunistic infection neoplasm ( Kaposi 's sarcoma ) , waste syndrome . Active hepatitis . Aphakia significantly increase risk retinal damage due absence lens . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Photosensitizing drug administer prior photopheresis treatment . Other investigational drug . Concurrent Treatment : Excluded : Other treatment use investigational device . Patients follow exclude : Inability tolerate extracorporeal volume loss leukocyteenrichment phase . Photosensitive disease . Symptoms toxic effect ( World Health Organization Criteria ) result previous therapy . Severe emotional , behavioral psychiatric problem opinion investigator would result poor compliance treatment regimen . Idiosyncratic hypersensitivity reaction 8MOP compound . Actively involved drug abuse . Aphakia significantly increase risk retinal damage due absence lens . Prior Medication : Excluded : Zidovudine ( AZT ) . Actively involved drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 1990</verification_date>
	<keyword>PUVA Therapy</keyword>
	<keyword>Methoxsalen</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>